Particle.news
Download on the App Store
7 ARTICLES
·
3mo ago

Johnson & Johnson Exceeds Q4 Expectations with Strong Cancer Drug Sales

The pharmaceutical giant reports a 5.3% revenue increase, bolstered by Darzalex sales, while forecasting challenges in 2025 due to generics and currency impacts.

Image
Image
Johnson and Johnson’s cancer drug sales increased by 19 per cent, lifted by Darzalex, its blockbuster multiple myeloma treatment
Image

Overview

  • Johnson & Johnson posted $22.52 billion in Q4 revenue, a 5.3% year-over-year increase, surpassing Wall Street estimates.
  • Cancer drug sales, led by Darzalex with $3 billion in revenue, rose 19%, driving growth in the pharmaceutical division.
  • The company recently announced a $14.6 billion acquisition of Intra-Cellular Therapies to expand its psychiatric drug portfolio.
  • J&J forecasts 2025 revenue of $90.9-$91.7 billion, slightly below analysts' expectations, citing currency headwinds and generic competition for Stelara.
  • Despite strong results, J&J shares fell over 1% as investors weighed ongoing talc litigation and slowing medical device sales in key markets like China.